Plus   Neg

Novavax Inc. (NVAX) Has Jumped To A New High On Study Results

Novavax Inc. (NVAX) reported results from its Phase 1/2 clinical trial in older adults of its NanoFlu recombinant influenza vaccine. The study showed improved immune responses compared to egg-based, high-dose flu vaccine.

Novavax has gapped open sharply higher Thursday morning and is now up 0.38 at $2.55. The stock has jumped to a new high for the year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT